Assessment and Tracking of Long-term Alefacept Safety (ATLAS)
Assessment and Tracking of Long-term Alefacept (LFA-3/IgG1 Fusion Protein) Safety (ATLAS)
Sponsor: Astellas Pharma Inc
Terminated
The Sponsor has made a decision, driven by business needs, to cease promotion, manufacturing, distribution and sales of Amevive
Other terminated trials from Astellas Pharma Inc
- Primary Mitochondrial Myopathy · Phase PHASE2 · May 2024
- Prostate Cancer · Jan 2024
- Anemia · Phase PHASE3 · Jun 2023
- Metastatic Castration Resistant Prostate Cancer · Phase PHASE1/PHASE2 · Nov 2022
- Breast Cancer · Phase PHASE2 · Sep 2022
More terminations from Astellas Pharma Inc
This observational or N/A phase trial investigates Psoriasis and is currently terminated or withdrawn. Astellas Pharma Inc leads this study, which shows 12 recorded versions since 2003 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
▶ Show 7 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated
-
Jun 2018 — Nov 2020 [monthly]
Terminated
-
May 2018 — Jun 2018 [monthly]
Terminated
-
Apr 2018 — May 2018 [monthly]
Terminated
Phase: PHASE4 → None
-
Aug 2017 — Apr 2018 [monthly]
Terminated PHASE4
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE4
First recorded
Jun 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Inc
For direct contact, visit the study record on ClinicalTrials.gov .